Skip to main content
Equibles
RNA logo

RNA · Atrium Therapeutics, Inc.

Track RNA — free

Use RNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.36 +0.01 (+0.10%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$177.21M
Shares
17.11M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.36 Open$10.37 Day$10.00–10.41 Available close range$10.35–16.54 Avg vol 30d233K Short int3.4M · 19.6% float · 19.8d Short vol41% Last earningsAug 13, 2026 DataFeb 2026–Sep 2026 Filing10-Q · Aug 13

The closing range uses available history since Feb 27, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-21.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$263.90M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
—
Trailing year
Short interest
19.6%
Latest settlement · 19.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −17%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −21%
trailing
Relative strength −39%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-5% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.59% of float · ▼ -3.7% MoM · 19.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
156 holders — 13F breadth
Squeeze score 65
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −37%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−17% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-5% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.59% of float · ▼ -3.7% MoM · 19.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
156 holders — 13F breadth
Price context
position in its available closing range
Range low $10 Now $10 · 0% Range high $17
vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RNA
Atrium Therapeutics, Inc.
this stock
$177.21M — — — 19.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
156
% held
89.2%
Net QoQ
-784.2K sh
Top holder
Sessa Capital IM, L.P.
Held Float
View
Held by Funds
Fund positions
158
View
Short & Settlement
Short Interest Falling
Shares short
3.4M
Days to cover
19.8d
Change
-129.3K sh
View
Short Volume
Short vol %
41%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
488
Value
$5.9K
As of
Aug 7, 2026
View
Off-Exchange
Off-exchange %
33.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
7
View
Earnings & Events
Earnings Calls
Last call
Aug 13, 2026
View

Performance

5D 20D 120D MTD YTD
RNA -29.0% -16.0% -21.1% -22.2% —
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -27.9% -14.2% -38.9% -21.9% —
Key facts CIK 2093101 CUSIP 04965N104 13F (30d) 64 filings 64 filers Visit website Investor relations